Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma
| Status: | Archived |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | April 2009 |
| End Date: | December 2011 |
Phase 1b' Open Label, Single Arm, Multicenter Trial to Evaluate the Safety, Tolerance, Response Rate and Immunological Effects of Repeated Intratumoral Injections of Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12(INXN-3001) in Response to an Oral Activator Ligand Administered in Intra-Patient Escalating Doses in Patients With Unresectable Stage III C or IV Malignant Melanoma
The purpose of this study is to test the safety of an investigational combination
drug/immunotherapy for the treatment of Stage III/IV melanoma.
This study will examine the effects of an oral Activator Ligand administration to modulate
the timing of gene expression of human IL-12 by adenovirus-transduced dendritic cells
injected into tumors.
We found this trial at
9
sites
Billings Clinic Based in Billings, Montana, Billings Clinic is a community-governed health care organization consisting...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials